Premium
Effect of lupeol and lupeol linoleate on lipemic – hepatocellular aberrations in rats fed a high cholesterol diet
Author(s) -
Sudhahar Varatharajan,
Ashokkumar Sekar,
Varalakshmi Palaninathan
Publication year - 2006
Publication title -
molecular nutrition and food research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.495
H-Index - 131
eISSN - 1613-4133
pISSN - 1613-4125
DOI - 10.1002/mnfr.200600134
Subject(s) - lupeol , cholesterol , cholic acid , medicine , endocrinology , dyslipidemia , chemistry , triterpene , deoxycholic acid , enzyme , bile acid , biochemistry , biology , obesity , pathology , alternative medicine
Abstract Cholesterol feeding has been often used to study the etiology of hypercholesterolaemia‐related metabolic disturbances. The aim of the present study is to investigate the effects of a pentacyclic triterpene, lupeol, and its ester derivative on hepatic abnormalities associated with hypercholesterolemic rats. Hypercholesterolaemia was induced in male Wistar rats by feeding them with a high cholesterol diet (HCD) containing normal rat chow supplemented with 4% cholesterol and 1% cholic acid, for 30 days. Lupeol and lupeol linoleate were supplemented (50 mg/kg body wt/day) during the last 15 days. Increased hepatic lipid profile along with abnormalities in lipid‐metabolizing enzyme activities were seen in hypercholesterolemic rats. An apparent increase in the expression of Acyl‐CoA cholesterol acyltransferase mRNA was seen in HCD fed rats. The activities of hepatic marker enzymes, which serve as indices of cellular injury, were altered in HCD fed rats. Treatment with triterpenes significantly modulated the abnormalities induced by hypercholesterolaemia. Also, an increased ( P >0.001) faecal excretion of cholesterol and bile acids were observed in lupeol and lupeol linoleate group when compared with HCD fed group. Therefore, it can be concluded that triterpenes treatment afforded substantial protection against the anomalies, which are manifested during the early stage of hypercholesterolemic atherogenesis.